Abstract
Some time in the early 2000s, the word “theranostics” (or “theragnostics”) started surfacing in the medical literature. Theranostics (from the Greek therapeuein “to treat medically” and gnosis “knowledge”) is the use of individual patient-level biological information in choosing the optimal therapy for that individual [1]. In the modern era of “personalized medicine”, theranostics is increasingly pursued in many branches of medicine in order to develop ever more effective treatment regimens. There are now many studies and reviews dedicated to theranostics, and even a journal bearing the name of this principle, detailing many different concepts on how to combine imaging and therapy using, for example, complex molecules [2] or nanotechnology [3]. However, it is rarely realized by either clinicians or scientists that nuclear medicine has been employing theranostics for nearly 80 years now. In fact, the very foundations of targeted therapy in nuclear medicine are those that are only now being adopted by other medical disciplines under the designation “theranostics”. The cornerstones of theranostics can be traced back to some of the most illustrious names among the founding fathers of nuclear medicine. Soon after Chiewitz and de Hevesy [4] described the uptake of radioactive P in the bones of rats, Erf and J.H. Lawrence (brother of the physicist Ernest O. Lawrence, who built the first cyclotron) applied this same radioisotope to patients suffering from leukaemia and polycythaemia vera [5]. Although this treatment certainly was not without success, it has since been superseded by more effective nonradioactive chemotherapy. Shortly afterwards Pecher [6] discovered that Sr accumulated in secondary bone tumours in animals, and subsequently successfully used this radioisotope to treat patients with painful bone metastases (unfortunately this work was immediately classified as secret and it took more than five decades for Sr to be registered as a therapeutic drug). These two studies are perhaps the earliest examples of diagnostic studies leading to targeted therapy of cancer using radionuclides. Around the same time the most prominent example of pure nuclear theranostic medicine emerged: the diagnosis and treatment of thyroid disorders using various isotopes of iodine. Hertz et al. in 1938 described the first study of thyroidal radioiodine uptake [7], and in 1942 Hertz and Roberts reported on the treatment of the first patients with Graves’ disease with radioiodine [8]. A short time later Seidlin et al. treated the first patient with metastatic thyroid cancer with radioiodine [9] – at the time this compoundwas so rare that radioiodinewas purified from the patient’s urine and readministered. During this therapy, additional metastases were identified using a Geiger counter and the first rudimentary dosimetry was performed. It is of course only with the benefit of hindsight that we can now say that this was the first application of theranostics in targeted molecular medicine through a specific molecular target, the sodium iodine symporter, long before any of these concepts were first described as “theranostics”. Indeed, even today it is hard to think of a single combination of targeted diagnostics and therapy that is more specific than radioiodine. F. A. Verburg (*) :A. Heinzel : F. M. Mottaghy Department of Nuclear Medicine, RWTH University Hospital Aachen, Pauwelsstrase 30, 52074 Aachen, Germany e-mail: fverburg@ukaachen.de
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: European Journal of Nuclear Medicine and Molecular Imaging
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.